← Eichor
Study identifier: NCT04181060 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Condition: Advanced Lung Non-Squamous Non-Small Cell Carcinoma · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma  ·  Sponsor: National Cancer Institute (NCI)

PhasePhase 3
Planned participants300
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (604)

Anchorage Associates in Radiation MedicineAnchorage, Alaska, United StatesSuspended
Anchorage Radiation Therapy CenterAnchorage, Alaska, United StatesSuspended
Alaska Breast Care and Surgery LLCAnchorage, Alaska, United StatesSuspended
Alaska Oncology and Hematology LLCAnchorage, Alaska, United StatesRecruiting
Alaska Women's Cancer CareAnchorage, Alaska, United StatesSuspended
Anchorage Oncology CentreAnchorage, Alaska, United StatesSuspended
Katmai Oncology GroupAnchorage, Alaska, United StatesRecruiting
Providence Alaska Medical CenterAnchorage, Alaska, United StatesSuspended
Fairbanks Memorial HospitalFairbanks, Alaska, United StatesRecruiting
Cancer Center at Saint Joseph'sPhoenix, Arizona, United StatesRecruiting
Mercy Hospital Fort SmithFort Smith, Arkansas, United StatesSuspended
CHI Saint Vincent Cancer Center Hot SpringsHot Springs, Arkansas, United StatesSuspended

+ 592 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04181060